![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Ipca Laboratories Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Cetirizine dihydrochloride, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2006-309 - Rev 01
This Chemical Type CEP, issued on August 03, 2017, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1084 associated with this CEP further emphasizes